50 filings analyzed. Top movers: Proem Acquisition Corp. I, Marygold Companies, Inc., Happy City Holdings Ltd, Viking Acquisition Corp I, VerifyMe, Inc..
8-K
Proem Acquisition Corp. I
Proem Acquisition Corp I (a blank-check company with ~$132.8M total assets) agreed to merge with Astro Digital US, Inc., an aerospace company providing satellite technology and services. The merger consideration is $525M base (plus exercise price adjustments), payable in Parent Common Shares post-Domestication. PIPE Investors commit $50M at $10/share. Company stockholders receive shares via Conversion Ratio; options/warrants convert; convertible notes convert. Transaction subject to shareholder approvals and standard closing conditions. Intended as Section 368 tax-reorganization.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
Marygold Companies, Inc.
The Marygold Companies, Inc. (public market cap ~$18.6M) has agreed to be acquired by Flower AcquireCo, LLC for $2.00 per share in cash. Supporting stockholders holding ~74.53% of voting power have committed to the merger via voting agreements dated September 25, 2026. The transaction requires stockholder consent, FCA approval for UK subsidiaries, and various regulatory filings; closing expected ~3 business days after final condition satisfaction.
▲ Likely positive
· significance 92 · 8-K Agent
SCHEDULE 13D/A
Happy City Holdings Ltd
Sky Way Innovation Holdings Limited lent Happy City Group Limited USD $1,000,000 on 17 April 2026, at 2.9% monthly interest (34.8% p.a.), due 17 October 2026, secured by 12,000,000 Class B ordinary shares of Happy City Holdings Limited. On 10 September 2026, the borrower defaulted on principal and accrued interest of USD $139,200. The lender immediately enforced its security and began selling the pledged shares without further notice or consent.
▼ Likely negative
· significance 92 · Ownership Agent
8-K
Viking Acquisition Corp I
Viking Acquisition Corp. I (SPAC, $236.4M assets) completed its previously announced business combination with NorthStar Earth Space Inc., a space situational awareness company, with closing expected September 30, 2026. The combined entity will trade as NorthStar Earth Space Enterprises, Inc. (NSTR) on NYSE American starting October 1, 2026, transferring from NYSE. No financial terms, share counts, or valuations are disclosed in this announcement.
— Neutral
· significance 92 · 8-K Agent
8-K
VerifyMe, Inc.
On February 11, 2026, Open World Ltd. (Cayman Islands, private blockchain/tokenization platform) entered a definitive merger agreement with VerifyMe Inc. (Nasdaq: VRME, public, ~$8.0M market cap). Upon closing, Open World shareholders will own ~90% of combined company; VerifyMe legacy shareholders ~10%. The 8-K exhibits audited FY 2025 financials for Open World (revenue $35.7M, net loss $20.2M), unaudited H1 2026 results (revenue $7.8M, net loss $5.9M), and unaudited pro forma combined statements. Transaction is reverse merger (Open World is accounting acquirer); minimum $1M cash closing condition for VerifyMe; $400K termination fee applies in certain scenarios. No deal has closed as of the SEC filing date.
▲ Likely positive
· significance 88 · 8-K Agent
SCHEDULE 13D/A
Hyperscale Data, Inc.
Milton C. Ault, III purchased 165,700 shares of Hyperscale Data Class A common stock between 09/15/2026 and 09/23/2026 at prices ranging from $0.1649 to $0.1859 per share, totaling approximately $28.5M. Simultaneously, Ault Company, Inc. purchased 850,000 shares between 09/16/2026 and 09/25/2026 at prices ranging from $0.1685 to $0.1852 per share, totaling approximately $147.5M. Combined, ~1.016M shares (~$176M) were acquired by Ault-controlled entities in a nine-day period.
▲ Likely positive
· significance 78 · Ownership Agent
8-K
Jaguar Health, Inc.
On September 25, 2026, Jaguar Health agreed to exchange a partitioned portion of a secured promissory note originally issued to Streeterville Capital, LLC (a Utah LLC) on January 19, 2021, for an unspecified number of freely tradable common shares. The specific dollar amount of the partitioned note and share count are redacted in the filing (shown as blanks). The original note's remaining balance is reduced by the partitioned amount; no other consideration changes hands. The exchange is structured under Securities Act Section 3(a)(9) to permit unrestricted resale under Rule 144, with holding period tacking to January 19, 2021.
— Neutral
· significance 78 · 8-K Agent
8-K
Bold Eagle Acquisition Corp.
Bold Eagle Acquisition Corp. (SPAC, $270M market value) agreed on September 25, 2026 to merge with REDL Intermediate Holdings, LLC, a cyber intelligence software and services provider to U.S. government/defense customers. Transaction values company at $1.25B enterprise value (Base Equity Value), with PIPE investors committing $335M ($275M convertible notes + $60M common stock). Post-closing structure: REDL becomes subsidiary of domesticated Delaware corporation (REDLattice Inc.). Sponsor (Eagle Equity Partners IV) retains 2.035M shares subject to earn-out vesting tied to stock price targets ($12.50, $15.00, $17.50) over 5-year period.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Kodiak Sciences Inc.
Kodiak announced positive Phase 3 DAYBREAK results (September 2026): Zenkuda (tarcocimab tedromer) achieved non-inferiority to aflibercept (p=0.0007) with 54% of patients on 6-month dosing intervals using treat-to-dryness criteria; tabirafusp-ted met vision primary endpoint (p=0.0036) and anatomical secondary endpoint (p=0.0001). The company plans a multi-indication BLA submission for Zenkuda in Q4 2026 covering wet AMD, diabetic retinopathy, and retinal vein occlusion based on five completed Phase 3 studies, with KSI-101 Phase 3 data expected December 2026 and potential two drug approvals by end of 2027/early 2028.
▲ Likely positive
· significance 78 · 8-K Agent
S-1/A
Rent the Runway, Inc.
Rent the Runway (RTR), a ~$15M market cap company, is conducting a rights offering distributing 4,225,352 subscription rights to existing shareholders at $3.55/share (greater of 15-day VWAP ending Sept 9 at $3.55 or through Sept 25 at $2.26). Up to $15M gross proceeds expected (~$14.3M net after ~$0.7M expenses). Investor Group (CHS, Nexus, STORY3) backstopped unsubscribed shares with no fee. Concurrently, RTR borrowed additional $10M term loan (Sept 1, 2026) and settled securities litigation for $9M ($6M cash + $3M stock). Stock traded at $1.67 on Sept 25—below subscription price. Nasdaq minimum MVPHS requirement is $15M; RTR was at $14.3M as of Sept 10, creating immediate delisting risk if not cured within 180 days.
▼ Likely negative
· significance 78 · Registration Agent
10-K
NATURAL ALTERNATIVES INTERNATIONAL INC
Natural Alternatives International Europe SA (Swiss subsidiary of NAIE, market cap ~$6.3M) entered into a credit agreement with UBS Switzerland AG for a maximum facility of 2,000,000 CHF (~$2.2M USD equivalent). The facility includes overdraft (up to 1.5M CHF), fixed advances (up to 1.5M CHF), and floating-rate loans. Security: assignment of all accounts receivable (valued at 6,374,145 CHF as of 30 June 2025). Key covenant: maintain minimum equity of 10M CHF. Auditor explicitly warns of going-concern doubt, inability to meet financial covenants, and insufficient cash if lender declares default.
▼ Likely negative
· significance 78 · Periodic Agent
8-K
HAIN CELESTIAL GROUP INC
On September 22, 2026, Hain Celestial received notice of failure to satisfy continued listing rules (Item 3.01) and reported departure of directors or officers with compensatory arrangement changes (Item 5.02). The 8-K does not specify which listing standard was breached, the identity of departing executives, compensation details, or remedial actions. Only the fact of the notices is disclosed; material specifics are absent from this filing.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
AZIO AI HOLDINGS, INC.
Azio AI Holdings (market cap ~$6.4M) entered a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville Advisors) on September 25, 2026. Yorkville commits up to $50 million for purchase of common shares at company's discretion during a 36-month commitment period. Company received $3 million upfront (less 4% discount = $2.88M net) with $500K due after registration statement effectiveness. Company issued 1,735,758 warrant shares (exercisable at $0.01/share) as commitment fee. Convertible promissory notes at 6% interest (18% post-default) mature September 25, 2027, with $1M monthly principal payments beginning April 6, 2027 or 30 days after Yorkville debentures repay. Advance share pricing ranges 96-97% of volume-weighted average price, subject to ownership caps (4.99%) and Nasdaq rules (19.99% Exchange Cap). Registration statement required; black-out periods limited to 20 days. Company granted warrants worth ~$17.4M at current prices if fully exercised. This facility materially expands equity available for issuance—potentially dilutive.
— Neutral
· significance 78 · 8-K Agent
8-K
Nexalin Technology, Inc.
On September 25, 2026, Nexalin Technology received notice of delisting or failure to satisfy continued listing requirements (Item 3.01). The filing does not specify which exchange, the specific rule violated, the timeline for remediation, or whether a transfer to another listing venue is occurring. No dollar amounts, share counts, or concrete remedial actions are disclosed in this filing stub.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences filed an 8-K on 2026-09-28 reporting Items 5.01 (Changes in Control of Registrant) and 5.07 (Submission of Matters to a Vote of Security Holders). The filing metadata provides no dollar amounts, counterparty names, share counts, percentages, or concrete details of the transaction or control change. Full substantive disclosure is not present in the available text.
— Neutral
· significance 78 · 8-K Agent
8-K
Polar Power, Inc.
Arthur Sams, CEO and founder of Polar Power, converted $614,700 in outstanding promissory notes into 683 Series A Convertible Preferred shares and a warrant to purchase 382,276 common shares at $1.34/share (3-year term). The exchange eliminates debt from the balance sheet, increases equity, and addresses the company's Nasdaq listing compliance issues. Approximately $7,908.84 in principal on one note remains outstanding; five notes totaling ~$492,300 in principal plus accrued interest were fully repaid and canceled.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
AAR CORP
AAR CORP is purchasing 65% equity interest (6,500 of 10,000 shares) of MRO Holdings, Inc. from MROH Intermediate Holdco LLC for approximately $4.0 billion enterprise value. Purchase price consists of: (i) estimated cash of ~$2.22B (after $22.5M escrow), plus/minus working capital and debt adjustments, and (ii) 5,783.894 shares of newly-created AAR Preferred Stock valued at $780,825,690 (~$135/share equivalent). Buyer has 65% option to purchase remaining 5% at formula price. Closing contingent on debt financing, regulatory approvals, and 15-business-day marketing period for debt offering.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Summit Therapeutics Inc.
AstraZeneca Holdings B.V. is investing $2.0 billion in Summit Therapeutics through purchase of approximately 108,955 shares of Class A Convertible Preferred Stock convertible into common stock at a 1:1,000 ratio, implying a per-share price of $18.36 (VWAP plus 10%). The transaction includes a clinical collaboration agreement to evaluate ivonescimab combined with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers, plus a non-binding MOU for future trials combining ivonescimab with AstraZeneca's ADC portfolio. Closing expected by end of week.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Azitra, Inc.
Azitra, Inc. (market cap ~$4.7M) entered into an at-the-market (ATM) sales agreement dated September 28, 2026 with A.G.P./Alliance Global Partners to offer and sell up to $3,503,232 of common stock. The sales agent will receive a 3.0% commission on gross proceeds from each sale. Shares will be offered on a continuous basis under the effective S-3 registration statement (File No. 333-280648, effective July 8, 2024). This is a standard equity financing mechanism allowing the company to raise capital opportunistically without discrete capital raises.
— Neutral
· significance 74 · 8-K Agent
8-K
Burford Capital Ltd
On September 25, 2026, a jury in Taction Technology v. Apple awarded $5.7 billion in damages. Burford Capital's financial entitlement is approximately $1.4 billion (split roughly equally between its balance sheet and investment funds), contingent on post-trial motions, appellate review, and collection. The filing emphasizes significant litigation and collection risks; verdicts of this magnitude rarely survive appellate process intact, and no cash has been received.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Adicet Bio, Inc.
Adicet Bio announced Phase 1 data on prula-cel (allogeneic gamma-delta CAR-T) in 22 efficacy-evaluable SLE/lupus nephritis patients (16 LN, 6 extra-renal SLE) as of August 28, 2026: 50% achieved complete renal response and 54% achieved DORIS remission at 12 months; all patients discontinued immunosuppressants and all but one tapered steroids to ≤5 mg prednisone; safety profile favorable (no Grade >2 CRS, no ICANS, no IEC-HS). Company plans pivotal trial start-up in Q4 2026, potentially expanding to non-renal SLE based on strong DORIS rate.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Transcode Therapeutics, Inc.
TransCode reported updated Phase 1a data for TTX-MC138 (anti-miR-10b) as of September 1, 2026: 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease; three patients remained progression-free at 12 months; disease control extended through six months in 35.7% of patients; no dose-limiting toxicities reported across all doses including 4.8 mg/kg; exploratory biomarker analysis showed treatment-associated antitumor immune activation. The study met its primary safety endpoint.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Cycurion, Inc.
Cycurion announced closed public safety engagements with the City of Chicago projected to generate $843,028 in 2026 revenue: $763,256 for go-live support, $22,645 for fire training, and $57,127 for CAD administration. If the CAD position continues at current monthly rate for 10 years, projected aggregate value is $3.43 million (not 2026 revenue). Revenue depends on continued authorization and contract terms.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Paramount Skydance Corp
Paramount Skydance Corporation announced the launch of senior secured first and second lien notes offerings totaling approximately $44.4 billion in aggregate principal amount. The net proceeds, combined with cash on hand, term loan financing ($5B committed, $7.5B Term B Loans, $32B first lien notes, $12.4B second lien notes), and $46.7 billion equity financing (PIPE) from Lawrence Ellison affiliates and others, will finance the $78 billion cash purchase of Warner Bros. Discovery at $31.00 per share plus ticking consideration, plus $1.1 billion for vested equity awards, plus $2.8 billion Netflix termination fee already paid. WBD merger agreement dated February 27, 2026; pro forma closing assumed October 6, 2026.
— Neutral
· significance 72 · 8-K Agent
8-K
MongoDB, Inc.
Chirantan Desai stepped down as President and CEO effective immediately to join Meta Platforms in a senior role. Dev Ittycheria, who led MongoDB as CEO from 2014–2025 and grew it from ~$35M to $2.3B+ in revenue, was appointed interim President and CEO. The Board initiated a permanent CEO search with external search firm; company reaffirmed Q3 and FY2027 guidance and is holding Investor Day Sept 29, 2026.
— Neutral
· significance 72 · 8-K Agent
8-K
Greenpro Capital Corp.
On September 28, 2026, Greenpro Capital Corp. sold all equity interests in six subsidiaries (Greenpro Resources HK Limited, Falcon Corporate Services Limited, Greenpro Financial Consulting Limited, and three others) principally providing corporate advisory and company-secretarial services in Hong Kong and China to Ms. Chen Yanhong, a company director and shareholder holding 14 shares. Cash consideration was HK$3.5 million (~$446,486 USD). The FA Entities generated approximately $1.35M of Greenpro's $2.07M total 2025 revenues (65% of service revenue). Proceeds will support general corporate purposes and working capital.
— Neutral
· significance 72 · 8-K Agent
8-K
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals' Board and Compensation Committee approved an amendment to increase the 2020 Long-Term Incentive Plan share reserve by 1,500,000 shares, raising the total available from 952,017 to 2,452,017 shares, pending shareholder approval. This allows for up to $500,000 annual equity grants to non-employee directors and increases equity pool available for employee and director compensation. The amendment is effective only upon stockholder approval.
— Neutral
· significance 72 · 8-K Agent
8-K
PEOPLES BANCORP INC
Peoples Bancorp Inc. (NASDAQ: PEBO) announced on September 28, 2026, that it has received all necessary regulatory approvals for its merger with Citizens National Corporation (OTCPK: CZNL), with Peoples as the surviving corporation. The Merger Agreement was dated April 20, 2026, and Citizens shareholders approved the merger on August 6, 2026. No specific deal value, share count, or exchange ratio is disclosed in this announcement.
▲ Likely positive
· significance 72 · 8-K Agent
10-K
PRECISION OPTICS CORPORATION, INC.
On September 25, 2026, Precision Optics and Main Street Bank amended the company's loan agreement (originally $500K revolver increased to $1.25M, plus $2.6M term loan). The company failed to meet its 1.20x minimum debt service coverage ratio for FY 6/30/2026. The bank waived this covenant but imposed a new $2M minimum liquidity covenant tied to a Main Street Bank account (failure = event of default), capped the $1.25M line of credit at $750K accessible immediately (remaining $500K blocked until DSCR recovers to 1.20x for 4 consecutive quarters), and charged a $5K modification fee.
▼ Likely negative
· significance 72 · Periodic Agent
10-K
Brightline Interactive, Inc./NV
Brightline Interactive (formerly The Glimpse Group) changed auditors from Turner, Stone Company, L.L.P. (Dallas) to GreenGrowth CPAs (Los Angeles), effective September 2026. The company executed a reverse stock split in 2026 (exact ratio not specified in exhibit). Prior auditor's report for FY2025 contained a going-concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations. The company also completed retrospective adjustments to discontinued operations (Notes 4 and 5).
▼ Likely negative
· significance 72 · Periodic Agent
8-K
AAR CORP
AAR Corp announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings (counterparty and purchase price not disclosed in this filing). In Q1 FY27 (ended Aug 31, 2026), AAR reported sales of $918.0M (+24% YoY), adjusted diluted EPS of $1.49 (+38% YoY), and adjusted EBITDA of $116.5M (+34% YoY). Net leverage improved to 1.81x. Guidance raised for full-year FY27 sales growth to low teens (vs. prior low double-digits to low teens).
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Inhibrx Biosciences, Inc.
Inhibrx disclosed interim Phase 2 HexAgon trial data for INBRX-106 (hexavalent OX40 agonist) combined with pembrolizumab in first-line recurrent/metastatic head-and-neck squamous cell carcinoma (HNSCC). In HPV-positive patients (n=10 combo vs n=9 mono), combination achieved 80% confirmed objective response rate versus 33% for pembrolizumab alone, with 90% vs 33% progression-free survival at 6 months. The company plans to expand Phase 2 enrollment by 50 additional HPV+ patients, targeting potential accelerated approval by end of 2028/early 2029. INBRX-109 (ozekibart, DR5 agonist) achieved primary endpoint in chondrosarcoma with HR=0.479 (P=0.0001), more than doubling median PFS to 5.52 vs 2.66 months; anticipated approval and commercial launch in 2H 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
FARADAY FUTURE INTELLIGENT ELECTRIC INC.
Faraday Future (FFAI, ~$223.5M market cap) agreed to sell its robotics business to AIxCrypto Holdings (AIXC) for $200M in AIXC common and preferred stock (non-binding term sheet dated Sept 25, 2026). FFAI will receive shares at the lower of $2.246 or 5-day VWAP; AIXC will rename to FF Robotics (FFR) and trade under ticker FFR. FFAI becomes controlling shareholder and enters holding-company model. Transaction includes 18-month lock-up, board seats, non-compete for 2 years. Robotics unit projects $7.1M revenue (2026E) and positive operating cash flow by Q3 2028.
▲ Likely positive
· significance 72 · 8-K Agent
8-K/A
ACCENDRA HEALTH INC/VA/
Edward A. Pesicka resigned as CEO effective October 5, 2026, and converted to independent contractor through March 31, 2029. Pesicka receives COBRA subsidy (18 months) and continued equity vesting; must execute broad release of claims and remains bound by non-compete/non-solicit covenants with tolled post-service restrictions. No cash separation amount disclosed.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
Quantum-Si Inc
Quantum-Si announced interim development results for its next-generation Proteus protein sequencing platform (in development, targeting Q2 2027 launch). In control peptide studies, Proteus delivered 30× more alignments per single chamber (median 4.09M vs 135.9k), 4.8× lower false discovery rate (1.36% vs 6.58%), and identified all 6 control peptides in every run vs. variable success on Platinum Pro. In 24-protein mixture tests, Proteus detected 4.3× more amino acids (269,864 vs 63,366), identified all 24 proteins vs. average 20.3 on Platinum, and detected 1.6–2.0× more peptides. Proteus uses 80M nanowell array vs Platinum's 2M wells; still uses developmental 18-amino-acid detection kit, with goal to detect all 20 AAs by end of 2026.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Ramaco Resources, Inc.
On September 25, 2026, a federal jury in West Virginia awarded Ramaco Resources, LLC (subsidiary of Ramaco Resources, Inc.) $30.0 million in damages against Federal Insurance Company and ACE American Insurance Company (Chubb subsidiaries) for wrongful denial of an insurance claim related to a November 2018 silo collapse at the Elk Creek preparation plant. The award comprises $2.5 million for aggravation/inconvenience and $27.5 million for net economic loss. Attorney's fees remain to be determined by the Court; defendants have 28 days for post-trial motions and 30 days from final judgment to appeal.
▲ Likely positive
· significance 71 · 8-K Agent
8-K
FATE THERAPEUTICS INC
Fate Therapeutics received a $15.0 million grant from California Institute for Regenerative Medicine (CIRM) through its competitive CLIN2 program to support RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in patients with refractory lupus nephritis. The trial will enroll approximately 53 patients with the primary endpoint of complete renal response at Week 26. No counterparties, equity dilution, or share issuances were disclosed.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
Exascale Labs Holdings Inc.
Exascale Labs (market cap ~$87.6M) reported FY2026 revenue of $14.8M (up 111% from $7.0M in FY2025), driven by 124% growth in GPU-as-a-Service. The company completed its SPAC merger with D. Boral ARC Acquisition I Corp. and began Nasdaq trading (XLAB/XLABW) on August 28, 2026, raising ~$11.8M in net cash proceeds. Strategic partnerships include a non-binding LOI with Compal Electronics for 800 VDC GPU validation and an MOU with EnergyBank for offshore wind-powered AI compute; the company reports a ~$300M qualified customer pipeline. However, FY2026 net loss widened to $12.2M from $7.7M, and gross margin remains thin at 16.3%.
▲ Likely positive
· significance 68 · 8-K Agent
8-K
Moleculin Biotech, Inc.
Moleculin announced publication of a peer-reviewed cardiac safety analysis in Frontiers in Cardiovascular Medicine examining 90 patients across five clinical trials of Annamycin (naxtarubicin). The pooled analysis, independently evaluated by Cleveland Clinic cardio-oncology, found no clinical or subclinical cardiotoxicity despite cumulative doses exceeding traditional anthracycline lifetime limits (median 660 mg/m²). Mean left ventricular ejection fraction remained stable at 60.6% baseline versus 60.0% post-treatment (p=0.84), with no dose-response relationship observed.
▲ Likely positive
· significance 62 · 8-K Agent
8-K
Brixmor Property Group Inc.
Brixmor Property Group (via EP/BRX Holdings LLC) entered into an arrangement agreement dated September 27, 2026 to acquire Slate Grocery REIT. The purchase price is $13.00 per unit plus daily Additional Consideration of $0.002482, payable in cash. The transaction is structured as a plan of arrangement under Ontario law and requires unitholder approval and court sanction. Closing targeted for on or after January 20, 2027, subject to customary closing conditions including financing (debt and equity commitments in place).
— Neutral
· significance 62 · 8-K Agent
8-K
VALLEY NATIONAL BANCORP
Valley National Bancorp agreed to acquire Bluevine Inc. for approximately $340 million (75% cash / 25% stock) in a definitive agreement announced September 28, 2026. Bluevine brings $2.1 billion in low-cost deposits (1.44% cost vs. Valley's 2.28%), 175,000 active small business customers, ~$169 million run-rate revenue, and approximately 180 R&D/engineering professionals across tech hubs. The transaction is expected to close early 2027 and deliver 8%+ 2028 EPS accretion with ~5% tangible book value dilution and ~3-year earn-back; pro forma CET1 ratio is 10.3%+ at close.
▲ Likely positive
· significance 62 · 8-K Agent
8-K
ONCOLYTICS BIOTECH INC
Oncolytics reported that substantially all planned clinical sites for its REO 033 randomized trial (evaluating pelareorep + FOLFIRI + bevacizumab vs. standard-of-care alone in RAS-mutant, MSS colorectal cancer) are now activated with multiple patients enrolled. Part A targets ~60 patients with primary endpoint of objective response rate (ORR). The company expects interim Part A data by year-end 2026 based on enrollment pace. FDA alignment provides a potential regulatory path: accelerated approval based on ORR, with full approval based on progression-free survival. REO 022 showed 33% ORR vs. ~6-11% historical benchmark, 16.6-month vs. ~5.7-month median PFS, and 27.0-month vs. ~11.2-month median overall survival.
▲ Likely positive
· significance 62 · 8-K Agent
8-K
CapsoVision, Inc
On September 25, 2026, CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool integrated into its CapsoView and CapsoCloud software platforms. The tool is designed to help physicians review small bowel capsule endoscopy studies by automatically recognizing and highlighting suspected abnormal lesions, reducing review time for adult and pediatric patients (age 2+) with suspected small bowel bleeding. The product had previously launched internationally, including in the European Union.
▲ Likely positive
· significance 62 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.